BioCentury
ARTICLE | Financial News

Excision raises $10M seed round

September 6, 2017 11:21 PM UTC

Gene editing company Excision BioTherapeutics Inc. (Philadelphia, Pa.) raised $10 million in a seed round led by Artis Ventures. Other undisclosed investors also participated.

Excision is developing therapeutics to treat viral infectious diseases by utilizing CRISPR. Excision's EBT101 is a CRISPR-Cas9 (CRISPR-associated protein 9)/gRNA multiplex biologic in preclinical development to treat HIV infection by eliminating viral reservoirs. In a 2016 paper in Scientific Reports, a team led by Excision co-founder and Temple University professor Kamel Khalili showed that a CRISPR-based HIV technique could excise the entire integrated HIV genome from infected cells with no detectable off-target effects and could protect against subsequent infection (see BioCentury Innovations, March 31, 2016)...